- Home
- ROIV vs EXLS Comparison
ROIV vs EXLS Comparison
Compare ROIV & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EXLS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 4.8B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EXLS |
|---|---|---|
| Price | $28.12 | $30.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $27.56 | ★ $46.80 |
| AVG Volume (30 Days) | ★ 4.5M | 1.9M |
| Earning Date | 02-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ 1.54 |
| Revenue | $29,053,000.00 | ★ $2,087,679,000.00 |
| Revenue This Year | N/A | $12.66 |
| Revenue Next Year | $594.84 | $10.54 |
| P/E Ratio | ★ N/A | $20.07 |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $8.73 | $26.94 |
| 52 Week High | $30.33 | $48.79 |
Technical Indicators
Market Signals| Indicator | ROIV | EXLS |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 48.64 |
| Support Level | $26.94 | $28.62 |
| Resistance Level | $30.33 | $31.50 |
| Average True Range (ATR) | 0.95 | 0.93 |
| MACD | -0.12 | 0.19 |
| Stochastic Oscillator | 79.20 | 74.66 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.